Winkelmann, Michael
Blumenberg, Viktoria
Rejeski, Kai
Bücklein, Veit L.
Ruzicka, Michael
Unterrainer, Marcus
Schmidt, Christian
Dekorsy, Franziska J.
Bartenstein, Peter
Ricke, Jens
von Bergwelt-Baildon, Michael
Subklewe, Marion
Kunz, Wolfgang G.
Funding for this research was provided by:
Bavarian Cancer Research Center
Förderung für Forschung und Lehre (1147)
Else Kröner-Fresenius-Stiftung
the German Cancer Consortium DKTK
Article History
Received: 29 September 2022
Accepted: 4 December 2022
First Online: 14 December 2022
Declarations
:
: All medical records and imaging studies were reviewed with the approval of the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 19–817).
: Informed consent was obtained from all individual participants included in the study.
: V.B. has received industry research support from Gilead, Novartis, Celgene, and Roche. K.R. declares having received research funding and travel support from Kite/Gilead and honoraria from Novartis. C.S. received travel support from Kite/Gilead. M.v.B.-B. received research funding and honoraria from Novartis, Kite Pharma, Miltenyi Biotec, Mologen, MSD, Astellas, and Roche. M.S. received industry research support from Amgen, Gilead, Miltenyi Biotec, MorphoSys, Roche, and Seattle Genetics; served as a consultant or advisor to Amgen, Bristol Myers Squibb, Celgene, Gilead, Pfizer, Novartis, and Roche; is on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics; and serves on the speaker’s bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. The remaining authors declare no competing financial interests.